See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $287B | 4.4x | 9.7x | |
| $188B | 3.0x | 7.6x | |
| $125B | 2.3x | 7.8x | |
| $118B | 2.7x | 8.0x | |
| $65.1B | 4.1x | 12.1x | |
| $53.8B | 6.2x | 20.1x | |
| $9.0B | 4.7x | -2.8x | |
| $8.2B | 3.9x | -44.7x | |
| $7.9B | 8.0x | 26.1x | |
| $7.9B | n/a | n/a | |
| $6.5B | 467142.3x | n/a | |
| $6.0B | 1.9x | -4.9x | |
| $4.5B | n/a | n/a | |
| $4.4B | 10.3x | 31.5x | |
| $3.5B | 5.1x | 14.4x | |
| $3.2B | 8.9x | 62.8x | |
| $2.4B | n/a | n/a | |
| $2.4B | 5.9x | 22.1x | |
| $2.4B | 21.8x | n/a | |
| $2.4B | 6.7x | 23.2x | |
| $2.2B | 12.5x | 53.1x | |
| $2.2B | 5.1x | -78.9x | |
| $2.1B | 8.7x | -5.9x | |
| $2.1B | 272.9x | -10.1x | |
| $1.9B | 7.4x | 29301.5x | |
| $1.9B | 2.0x | 5.6x | |
| $1.5B | n/a | n/a | |
| $1.4B | 4.3x | 58.1x | |
| $1.4B | n/a | n/a | |
| $1.3B | 8.4x | 9.2x | |
| $1.3B | 6.9x | 18.6x | |
| $1.2B | 458.8x | -8.0x | |
| $1.2B | 413.5x | -4.5x | |
| $1.2B | 5.7x | -41.2x | |
| $1.1B | 6.6x | 22.1x | |
| $1.1B | 30.0x | 112.9x | |
| $1.0B | 33.2x | -28.0x | |
| $998M | 12.0x | -30.2x | |
| $881M | 18.2x | -4.5x | |
| $866M | 5.5x | 11.7x | |
| $831M | 3.5x | 11.2x | |
| $797M | 4.0x | -15.7x | |
| $736M | 3.9x | n/a | |
| $716M | 16.4x | -4.8x | |
| $704M | 73670.1x | n/a | |
| $663M | 13.2x | -11.6x | |
| $607M | 7.3x | -58.0x | |
| $598M | 0.6x | 1.6x | |
| $572M | 540.5x | -29.2x | |
| $545M | 23762.3x | -3.1x | |
| $534M | 430.7x | -1.7x | |
| $515M | 6.9x | -4.9x | |
| $515M | n/a | n/a | |
| $510M | n/a | n/a | |
| $500M | n/a | n/a | |
| $483M | n/a | -7.7x | |
| $444M | n/a | n/a | |
| $441M | 78.9x | n/a | |
| $428M | 20.1x | -0.8x | |
| $418M | 1.9x | n/a | |
| $394M | n/a | -2.3x | |
| $349M | 18.2x | -1223.8x | |
| $346M | 1.9x | 7.9x | |
| $305M | n/a | n/a | |
| $283M | n/a | n/a | |
| $282M | 1.5x | 6.9x | |
| $282M | n/a | -11.0x | |
| $273M | 33573586.3x | -9.9x | |
| $250M | n/a | -5.5x | |
| $183M | 5.5x | n/a | |
| $167M | 15.3x | -4.3x | |
| $160M | n/a | n/a | |
| $155M | 1.2x | n/a | |
| $148M | 1688070.7x | -5.9x | |
| $144M | n/a | n/a | |
| $143M | 1.9x | -0.5x | |
| $136M | 46.8x | -7.1x | |
| $136M | n/a | n/a | |
| $135M | 60863.8x | -0.7x | |
| $128M | 102.8x | -2.7x | |
| $128M | 1.0x | 3.5x | |
| $127M | 2.5x | -55.0x | |
| $127M | n/a | n/a | |
| $125M | n/a | n/a | |
| $123M | n/a | n/a | |
| $117M | 1220.1x | n/a | |
| $105M | n/a | n/a | |
| $94.0M | n/a | -3.8x | |
| $90.9M | n/a | n/a | |
| $89.5M | n/a | n/a | |
| $86.3M | 14.7x | n/a | |
| $82.0M | n/a | n/a | |
| $76.7M | n/a | -0.4x | |
| $75.3M | 5193.2x | n/a | |
| $62.6M | 19.9x | -1.7x | |
| $61.0M | 8.2x | n/a | |
| $58.4M | n/a | n/a | |
| $50.8M | n/a | n/a | |
| $47.5M | n/a | n/a | |
| $45.9M | n/a | n/a | |
| $44.0M | n/a | n/a | |
| $43.1M | n/a | n/a | |
| $42.9M | 18.1x | n/a | |
| $41.2M | n/a | -1.2x | |
| $40.6M | n/a | -0.5x | |
| $27.9M | 5.6x | -0.9x | |
| $27.4M | n/a | n/a | |
| $21.6M | n/a | -0.2x | |
| $20.1M | n/a | n/a | |
| $19.8M | 13.6x | -1.2x | |
| $19.3M | 292.6x | n/a | |
| $18.2M | n/a | n/a | |
| $17.1M | 2.4x | n/a | |
| $16.6M | n/a | n/a | |
| $15.1M | 13.8x | -0.5x | |
| $9.8M | 0.2x | -0.1x | |
| $9.5M | 174.1x | n/a | |
| $6.4M | 2.6x | n/a | |
| $5.6M | 1.8x | -0.4x | |
| $3.6M | 173.2x | n/a | |
| $1.9M | 0.3x | n/a | |
| $1.9M | 0.2x | n/a | |
| -$7.5M | -0.1x | n/a | |
| -$7.9M | -2.8x | n/a | |
| -$8.7M | -3155.3x | n/a | |
| -$20.8M | -3.2x | 0.2x | |
| -$28.7M | -2.7x | 0.2x | |
| -$33.9M | -206.5x | n/a | |
| -$61.8M | -9.7x | n/a | |
| -$75.0M | n/a | n/a | |
| -$87.1M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies